Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1672619 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $52.97Day −1.47%Mkt cap $3.2B1Y +163.9%Off 52W high −5.1%Vol (1Y) 82.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 843 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest14.2% of sh out |
| Days to cover9.4d |
| 13F net flow (QoQ)−4.69% |
| Top-10 13F concentration60.3% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$98.8M |
| ROE−27.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+244.0% |
| 1Y+163.9% |
| 3Y+179.7% |
| Since incept. (ann.)+31.0% |
Total return through 2026-07-29 · series begins 2023-03-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)82.5% |
| Ann. volatility (3Y)78.2% |
| Sharpe (1Y)1.53 |
| Sharpe (3Y)0.81 |
| Max drawdown (1Y)−36.8% |
| Max drawdown (3Y)−49.5% |
| Beta (3Y vs SPY)0.21 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 8.0M | $312M | 13.07% | +0.0% |
| FMR LLC | 6.8M | $268M | 11.21% | −3.9% |
| Polar Capital Holdings Plc | 5.1M | $199M | 8.32% | +44.2% |
| BlackRock, Inc. | 3.7M | $144M | 6.05% | +2.0% |
| Commodore Capital LP | 3.3M | $128M | 5.38% | −30.2% |
| Vestal Point Capital, LP | 3.3M | $127M | 5.34% | −15.1% |
| Bellevue Group AG | 2.3M | $91M | 3.81% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $85M | 3.56% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 103.9% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 5,273,791 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.38 | — | — | — |
| 2025-09-30 | 2025-11-12 | −$0.32 | — | — | — |
| 2025-06-30 | 2025-08-13 | −$0.49 | — | — | — |
| 2025-03-31 | 2025-05-14 | −$0.57 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
